Angiogenesis and bone repair

Drug Discovery Today

Volumn 8, Issue 21, 2003, Pages 980-989

  Carano, Richard A D ^a   Filvaroff, Ellen H ^a  

^a GENENTECH INC   (United States)

Author keywords

Angiogenesis; Bone Morphogenetic Proteins (BMPs); Bone repair; Cell biology; Drug Discovery; Fibroblast Growth Factors; Fracture; Molecular Medicine; Osteogenesis; Pharmaceutical Science; Transforming Growth Factor Betas; Vascular Endothelial Growth Factor

Indexed keywords

ACTIVIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; GROWTH DIFFERENTIATION FACTOR 5; GROWTH HORMONE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOGENIC PROTEIN 1; PARATHYROID HORMONE; PROSTAGLANDIN; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; VASCULOTROPIN;

ANGIOGENESIS; BABOON; BONE INJURY; BONE METABOLISM; BONE REMODELING; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFECT; FRACTURE; FRACTURE HEALING; FRACTURE NONUNION; HUMAN; NONHUMAN; OSTEOLYSIS; RABBIT; REVIEW;

ANIMALS; BONE AND BONES; BONE MORPHOGENETIC PROTEINS; BONE REGENERATION; CELL COMMUNICATION; ENDOTHELIAL CELLS; FRACTURE HEALING; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOBLASTS; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0345305374     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02866-6     Document Type: Review

References (152)

1. Haller A. Experimentorum de ossiem formatione. Opera minora. 2:1763;400 Francisci Grasset.
2. Hunter J. Treatise on the Blood, Inflammation and Gunshot Wounds. 1794;Thomas Bradford.
3. Trueta J. The role of the vessels in osteogenesis. J. Bone Jt Surg. Ser A. 45B:1963;402-418.
4. Burkhardt R., et al. Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age: a comparative histomorphometric study. Bone. 8:1987;157-164.
5. Glowacki, J. (1998) Angiogenesis in fracture repair. Clin. Orthop. (Suppl 355), S82-S89.
6. Praemer A., et al. Musculoskeletal Conditions in the United States. 1992;85-124 The American Academy of Orthopaedic Surgeons.
7. Einhorn T.A. Enhancement of fracture-healing. J. Bone Joint Surg. Am. 77:1995;940-956.
8. Hausman M.R., et al. Prevention of fracture healing in rats by an inhibitor of angiogenesis. Bone. 29:2001;560-564.
9. Einhorn, T.A. (1998) The cell and molecular biology of fracture healing. Clin. Orthop. (Suppl 355), S7-21.
10. Mandracchia V.J., et al. Current concepts of bone healing. Clin. Podiatr. Med. Surg. 18:2001;55-77.
11. Hadjiargyrou M., et al. Transcriptional profiling of bone regeneration. Insight into the molecular complexity of wound repair. J. Biol. Chem. 277:2002;30177-30182.
12. Gerstenfeld L.C., et al. Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. J. Cell. Biochem. 88:2003;873-884.
13. Grundnes O., Reikeras O. The importance of the hematoma for fracture healing in rats. Acta Orthop. Scand. 64:1993;340-342.
14. Mizuno K., et al. The osteogenetic potential of fracture haematoma. Subperiosteal and intramuscular transplantation of the haematoma. J. Bone Joint Surg. Br. 72:1990;822-829.
15. Street J., et al. Is human fracture hematoma inherently angiogenic? Clin. Orthop. 378:2000;224-237.
16. Street J.T., et al. The angiogenic response to skeletal injury is preserved in the elderly. J. Orthop. Res. 19:2001;1057-1066.
17. Barnes G.L., et al. Growth factor regulation of fracture repair. J. Bone Miner. Res. 14:1999;1805-1815.
18. Hauser C.J., et al. The immune microenvironment of human fracture/soft-tissue hematomas and its relationship to systemic immunity. J. Trauma. 42:1997;895-903.
19. Street J., et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc. Natl. Acad. Sci. U. S. A. 99:2002;9656-9661.
20. Le A.X., et al. Molecular aspects of healing in stabilized and non-stabilized fractures. J. Orthop. Res. 19:2001;78-84.
21. Rhinelander F.W. Tibial blood supply in relation to fracture healing. Clin. Orthop. 105:1974;34-81.
22. Brighton C.T., Hunt R.M. Early histological and ultrastructural changes in medullary fracture callus. J. Bone Joint Surg. Am. 73:1991;832-847.
23. Marsh, D. (1998) Concepts of fracture union, delayed union, and nonunion. Clin. Orthop. (Suppl 355), S22-S30.
24. Ferguson C., et al. Does adult fracture repair recapitulate embryonic skeletal formation? Mech. Dev. 87:1999;57-66.
25. Tatsuyama K., et al. Expression of various growth factors for cell proliferation and cytodifferentiation during fracture repair of bone. Eur. J. Histochem. 44:2000;269-278.
26. Gerber H.P., Ferrara N. Angiogenesis and bone growth. Trends Cardiovasc. Med. 10:2000;223-228.
27. Street J., et al. Multiple angiogenic cytokines protect against osteoblast apoptosis. Surg. Forum. L1:2000;465-467.
28. Zelzer E., et al. Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development. 129:2002;1893-1904.
29. Gerber H.P., et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med. 5:1999;623-628.
30. Haigh J.J., et al. Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. Development. 127:2000;1445-1453.
31. Ryan A.M., et al. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol. Pathol. 27:1999;78-86.
32. Chu T.W., et al. Effect of endothelial growth fracture in fracture healing]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 16:2002;75-78.
33. Peng H., et al. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J. Clin. Invest. 110:2002;751-759.
34. Harada S., et al. Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. J. Clin. Invest. 93:1994;2490-2496.
35. Doan N., et al. In vitro effects of therapeutic ultrasound on cell proliferation, protein synthesis, and cytokine production by human fibroblasts, osteoblasts, and monocytes. J. Oral Maxillofac. Surg. 57:1999;409-419.
36. Claffey K.P., et al. Fibroblast growth factor 2 activation of stromal cell vascular endothelial growth factor expression and angiogenesis. Lab. Invest. 81:2001;61-75.
37. Deckers M.M., et al. Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology. 143:2002;1545-1553.
38. Yeh L.C., Lee J.C. Osteogenic protein-1 increases gene expression of vascular endothelial growth factor in primary cultures of fetal rat calvaria cells. Mol. Cell. Endocrinol. 153:1999;113-124.
39. Ferrara N., et al. The biology of VEGF and its receptors. Nat. Med. 9:2003;669-676.
40. Midy V., Plouet J. Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts. Biochem. Biophys. Res. Commun. 199:1994;380-386.
41. Deckers M.M., et al. Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. Endocrinology. 141:2000;1667-1674.
42. Mayr-Wohlfart U., et al. Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts. Bone. 30:2002;472-477.
43. Niida S., et al. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J. Exp. Med. 190:1999;293-298.
44. Engsig M.T., et al. Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J. Cell Biol. 151:2000;879-889.
45. Nakagawa M., et al. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett. 473:2000;161-164.
46. Eckardt H., et al. Effects of locally applied vascular endothelial growth factor (VEGF) and VEGF-inhibitor to the rabbit tibia during distraction osteogenesis. J. Orthop. Res. 21:2003;335-340.
47. Hiltunen M.O., et al. Adenovirus-mediated VEGF-A gene transfer induces bone formation in vivo. FASEB J. 17:2003;1147-1149.
48. Tarkka T., et al. Adenoviral VEGF-A gene transfer induces angiogenesis and promotes bone formation in healing osseous tissues. J. Gene Med. 5:2003;560-566.
49. Colnot C., et al. Altered fracture repair in the absence of MMP9. Development. 130:2003;4123-4133.
50. Ilizarov G.A., et al. Reconstruction of large defects of blood vessels on extremities by means of a gradual distraction. (An experimental study). Acta Chir. Plast. 22:1980;156-165.
51. Aronson J. Experimental and clinical experience with distraction osteogenesis. Cleft Palate Craniofac. J. 31:1994;473-481.
52. Pufe T., et al. Quantitative measurement of the splice variants 120 and 164 of the angiogenic peptide vascular endothelial growth factor in the time flow of fracture healing: a study in the rat. Cell Tissue Res. 309:2002;387-392.
53. Uchida S., et al. Vascular endothelial growth factor is expressed along with its receptors during the healing process of bone and bone marrow after drill-hole injury in rats. Bone. 32:2003;491-501.
54. Wang D.S., et al. Anabolic effects of 1,25-dihydroxyvitamin D3 on osteoblasts are enhanced by vascular endothelial growth factor produced by osteoblasts and by growth factors produced by endothelial cells. Endocrinology. 138:1997;2953-2962.
55. Bouletreau P.J., et al. Hypoxia and VEGF up-regulate BMP-2 mRNA and protein expression in microvascular endothelial cells: implications for fracture healing. Plast. Reconstr. Surg. 109:2002;2384-2397.
56. Bouletreau P.J., et al. Factors in the fracture microenvironment induce primary osteoblast angiogenic cytokine production. Plast. Reconstr. Surg. 110:2002;139-148.
57. Goad D.L., et al. Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. Endocrinology. 137:1996;2262-2268.
58. Wang D.S., et al. Increase of vascular endothelial growth factor mRNA expression by 1,25-dihydroxyvitamin D3 in human osteoblast-like cells. J. Bone Miner. Res. 11:1996;472-479.
59. Saadeh P.B., et al. Transforming growth factor-beta1 modulates the expression of vascular endothelial growth factor by osteoblasts. Am. J. Physiol. 277:1999;C628-C637.
60. Harper J., et al. Neuropilin-1 expression in osteogenic cells: down-regulation during differentiation of osteoblasts into osteocytes. J. Cell. Biochem. 81:2001;82-92.
61. Kohno S., et al. Expression of vascular endothelial growth factor and the effects on bone remodeling during experimental tooth movement. J. Dent. Res. 82:2003;177-182.
62. Maes C., et al. Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech. Dev. 111:2002;61-73.
63. Carlevaro M.F., et al. Vascular endothelial growth factor (VEGF) in cartilage neovascularization and chondrocyte differentiation: auto-paracrine role during endochondral bone formation. J. Cell Sci. 113:2000;59-69.
64. Klagsbrun M. The fibroblast growth factor family: structural and biological properties. Prog. Growth Factor Res. 1:1989;207-235.
65. Gonzalez A.M., et al. Distribution of fibroblast growth factor (FGF)-2 and FGF receptor-1 messenger RNA expression and protein presence in the mid-trimester human fetus. Pediatr. Res. 39:1996;375-385.
66. Nakamura T., et al. Stimulation of endosteal bone formation by systemic injections of recombinant basic fibroblast growth factor in rats. Endocrinology. 136:1995;1276-1284.
67. Nakamura K., et al. Stimulation of bone formation by intraosseous injection of basic fibroblast growth factor in ovariectomised rats. Int. Orthop. 22:1998;49-54.
68. Liang H., et al. Bone anabolic effects of basic fibroblast growth factor in ovariectomized rats. Endocrinology. 140:1999;5780-5788.
69. Kawaguchi H., et al. Stimulation of fracture repair by recombinant human basic fibroblast growth factor in normal and streptozotocin-diabetic rats. Endocrinology. 135:1994;774-781.
70. Bland Y.S., et al. Exogenous fibroblast growth factors-1 and -2 do not accelerate fracture healing in the rabbit. Acta Orthop. Scand. 66:1995;543-548.
71. Andreshak J.L., et al. Tibial segmental defect repair: chondrogenesis and biomechanical strength modulated by basic fibroblast growth factor. Anat. Rec. 248:1997;198-204.
72. Inui K., et al. Local application of basic fibroblast growth factor minipellet induces the healing of segmental bony defects in rabbits. Calcif. Tissue Int. 63:1998;490-495.
73. Kato T., et al. Single local injection of recombinant fibroblast growth factor-2 stimulates healing of segmental bone defects in rabbits. J. Orthop. Res. 16:1998;654-659.
74. Nakamura T., et al. Recombinant human basic fibroblast growth factor accelerates fracture healing by enhancing callus remodeling in experimental dog tibial fracture. J. Bone Miner. Res. 13:1998;942-949.
75. Radomsky M.L., et al. Novel formulation of fibroblast growth factor-2 in a hyaluronan gel accelerates fracture healing in nonhuman primates. J. Orthop. Res. 17:1999;607-614.
76. Kawaguchi H., et al. Acceleration of fracture healing in nonhuman primates by fibroblast growth factor-2. J. Clin. Endocrinol. Metab. 86:2001;875-880.
77. Montesano R., et al. Basic fibroblast growth factor induces angiogenesis in vitro. Proc. Natl. Acad. Sci. U. S. A. 83:1986;7297-7301.
78. Hayek A., et al. An in vivo model for study of the angiogenic effects of basic fibroblast growth factor. Biochem. Biophys. Res. Commun. 147:1987;876-880.
79. Collin-Osdoby P., et al. Basic fibroblast growth factor stimulates osteoclast recruitment, development, and bone pit resorption in association with angiogenesis in vivo on the chick chorioallantoic membrane and activates isolated avian osteoclast resorption in vitro. J. Bone Miner. Res. 17:2002;1859-1871.
80. Globus R.K., et al. Regulation of bovine bone cell proliferation by fibroblast growth factor and transforming growth factor beta. Endocrinology. 123:1988;98-105.
81. Nakajima F., et al. Spatial and temporal gene expression in chondrogenesis during fracture healing and the effects of basic fibroblast growth factor. J. Orthop. Res. 19:2001;935-944.
82. Simmons H.A., Raisz L.G. Effects of acid and basic fibroblast growth factor and heparin on resorption of cultured fetal rat long bones. J. Bone Miner. Res. 6:1991;1301-1305.
83. Hurley M.M., et al. Basic fibroblast growth factor induces osteoclast formation in murine bone marrow cultures. Bone. 22:1998;309-316.
84. Nakagawa N., et al. Basic fibroblast growth factor induces osteoclast formation by reciprocally regulating the production of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in mouse osteoblastic cells. Biochem. Biophys. Res. Commun. 265:1999;158-163.
85. Kawaguchi H., et al. Direct and indirect actions of fibroblast growth factor 2 on osteoclastic bone resorption in cultures. J. Bone Miner. Res. 15:2000;466-473.
86. Warren S.M., et al. The BMP antagonist noggin regulates cranial suture fusion. Nature. 422:2003;625-629.
87. Lane N.E., et al. Basic fibroblast growth factor forms new trabeculae that physically connect with pre-existing trabeculae, and this new bone is maintained with an anti-resorptive agent and enhanced with an anabolic agent in an osteopenic rat model. Osteoporos. Int. 14:2003;374-382.
88. Urist M.R. Bone: formation by autoinduction. Science. 150:1965;893-899.
89. Wozney J.M., et al. Novel regulators of bone formation: molecular clones and activities. Science. 242:1988;1528-1534.
90. Celeste A.J., et al. Identification of transforming growth factor beta family members present in bone-inductive protein purified from bovine bone. Proc. Natl. Acad. Sci. U. S. A. 87:1990;9843-9847.
91. Wozney J.M., Rosen V. Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin. Orthop. 346:1998;26-37.
92. Chang H., et al. Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocr. Rev. 23:2002;787-823.
93. Cho T.J., et al. Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J. Bone Miner. Res. 17:2002;513-520.
94. Joyce M.E., et al. Transforming growth factor-beta in the regulation of fracture repair. Orthop. Clin. North Am. 21:1990;199-209.
95. Lind M., et al. Transforming growth factor-beta enhances fracture healing in rabbit tibiae. Acta Orthop. Scand. 64:1993;553-556.
96. Margolin M.D., et al. Maxillary sinus augmentation in the non-human primate: a comparative radiographic and histologic study between recombinant human osteogenic protein-1 and natural bone mineral. J. Periodontol. 69:1998;911-919.
97. Muschler G.F., et al. Evaluation of human bone morphogenetic protein 2 in a canine spinal fusion model. Clin. Orthop. 308:1994;229-240.
98. Heckman J.D., et al. Bone morphogenetic protein but not transforming growth factor-beta enhances bone formation in canine diaphyseal nonunions implanted with a biodegradable composite polymer. J. Bone Joint Surg. Am. 81:1999;1717-1729.
99. Nielsen H.M., et al. Local injection of TGF-beta increases the strength of tibial fractures in the rat. Acta Orthop. Scand. 65:1994;37-41.
100. Noda M., Camilliere J.J. In vivo stimulation of bone formation by transforming growth factor-beta. Endocrinology. 124:1989;2991-2994.
101. Ripamonti U., et al. Complete regeneration of bone in the baboon by recombinant human osteogenic protein-1 (hOP-1, bone morphogenetic protein-7). Growth Factors. 13:1996;273-289.
102. Sampath T.K., et al. Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J. Biol. Chem. 267:1992;20352-20362.
103. Sakai R., et al. Activin increases bone mass and mechanical strength of lumbar vertebrae in aged ovariectomized rats. Bone. 27:2000;91-96.
104. Bax B.E., et al. Bone morphogenetic protein-2 increases the rate of callus formation after fracture of the rabbit tibia. Calcif. Tissue Int. 65:1999;83-89.
105. Beck L.S., et al. Rapid publication. TGF-beta 1 induces bone closure of skull defects. J. Bone Miner. Res. 6:1991;1257-1265.
106. Cook S.D., et al. Recombinant human bone morphogenetic protein-7 induces healing in a canine long-bone segmental defect model. Clin. Orthop. 301:1994;302-312.
107. Cook S.D., et al. The effect of recombinant human osteogenic protein-1 on healing of large segmental bone defects. J. Bone Joint Surg. Am. 76:1994;827-838.
108. Cook S.D., et al. In vivo evaluation of recombinant human osteogenic protein (rhOP-1) implants as a bone graft substitute for spinal fusions. Spine. 19:1994;1655-1663.
109. Friedlaender G.E., et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J. Bone Joint Surg. Am. 83A:(Suppl 1):2001;S151-S158.
110. Geesink R.G., et al. Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibular defect. J. Bone Joint Surg. Br. 81:1999;710-718.
111. Valentin-Opran A., et al. Clinical evaluation of recombinant human bone morphogenetic protein-2. Clin. Orthop. 395:2002;110-120.
112. Reddi A.H. Bone morphogenetic proteins: from basic science to clinical applications. J. Bone Joint Surg. Am. 83A:(Suppl 1):2001;S1-S6.
113. Rosier, R.N. et al. (1998) The potential role of transforming growth factor beta in fracture healing. Clin. Or56thop. (Suppl 355), S294-S300.
114. Bostrom, M.P. and Asnis, P. (1998) Transforming growth factor beta in fracture repair. Clin. Orthop. (Suppl 355), S124-S131.
115. Joyce M.E., et al. Transforming growth factor-beta and the initiation of chondrogenesis and osteogenesis in the rat femur. J. Cell Biol. 110:1990;2195-2207.
116. Critchlow M.A., et al. The effect of exogenous transforming growth factor-beta 2 on healing fractures in the rabbit. Bone. 16:1995;521-527.
117. Tielinen L., et al. Inability of transforming growth factor-beta 1, combined with a bioabsorbable polymer paste, to promote healing of bone defects in the rat distal femur. Arch. Orthop. Trauma Surg. 121:2001;191-196.
118. Sumner D.R., et al. Enhancement of bone ingrowth by transforming growth factor-beta. J. Bone Joint Surg. Am. 77:1995;1135-1147.
119. Lind M., et al. Transforming growth factor-beta 1 stimulates bone ongrowth to weight-loaded tricalcium phosphate coated implants: an experimental study in dogs. J. Bone Joint Surg. Br. 78:1996;377-382.
120. Erlebacher A., et al. Osteoblastic responses to TGF-beta during bone remodeling. Mol. Biol. Cell. 9:1998;1903-1918.
121. Wang E.A., et al. Recombinant human bone morphogenetic protein induces bone formation. Proc. Natl. Acad. Sci. U. S. A. 87:1990;2220-2224.
122. Croteau S., et al. Bone morphogenetic proteins in orthopedics: from basic science to clinical practice. Orthopedics. 22:1999;686-695.
123. Yasko A.W., et al. The healing of segmental bone defects, induced by recombinant human bone morphogenetic protein (rhBMP-2). A radiographic, histological, and biomechanical study in rats. J. Bone Joint Surg. Am. 74:1992;659-670.
124. Luppen C.A., et al. Recombinant human bone morphogenetic protein-2 enhances osteotomy healing in glucocorticoid-treated rabbits. J. Bone Miner. Res. 17:2002;301-310.
125. Sandhu H.S., et al. Evaluation of rhBMP-2 with an OPLA carrier in a canine posterolateral (transverse process) spinal fusion model. Spine. 20:1995;2669-2682.
126. Bouxsein M.L., et al. Recombinant human bone morphogenetic protein-2 accelerates healing in a rabbit ulnar osteotomy model. J. Bone Joint Surg. Am. 83A:2001;1219-1230.
127. Burkus J.K., et al. Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2. Spine. 27:2002;2396-2408.
128. Ramoshebi L.N., Ripamonti U. Osteogenic protein-1, a bone morphogenetic protein, induces angiogenesis in the chick chorioallantoic membrane and synergizes with basic fibroblast growth factor and transforming growth factor-beta1. Anat. Rec. 259:2000;97-107.
129. Yamashita H., et al. Growth/differentiation factor-5 induces angiogenesis in vivo. Exp. Cell Res. 235:1997;218-226.
130. Hay E., et al. Bone morphogenetic protein-2 promotes osteoblast apoptosis through a Smad-independent, protein kinase C-dependent signaling pathway. J. Biol. Chem. 276:2001;29028-29036.
131. Yoon S.T., Boden S.D. Osteoinductive molecules in orthopaedics: basic science and preclinical studies. Clin. Orthop. 395:2002;33-43.
132. Critchlow M.A., et al. The effects of age on the response of rabbit periosteal osteoprogenitor cells to exogenous transforming growth factor-beta 2. J. Cell Sci. 107:1994;499-516.
133. Fleet J.C., et al. The effects of aging on the bone inductive activity of recombinant human bone morphogenetic protein-2. Endocrinology. 137:1996;4605-4610.
134. Sakai R., et al. Local administration of activin promotes fracture healing in the rat fibula fracture model. Bone. 25:1999;191-196.
135. Winet H., et al. A control model for tibial cortex neovascularization in the bone chamber. J. Bone Miner. Res. 5:1990;19-30.
136. Paralkar V.M., et al. An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc. Natl. Acad. Sci. U. S. A. 100:2003;6736-6740.
137. Clark J.D., et al. Stratigraphic, chronological and behavioural contexts of Pleistocene Homo sapiens from Middle Awash, Ethiopia. Nature. 423:2003;747-752.
138. White T.D., et al. Pleistocene Homo sapiens from Middle Awash, Ethiopia. Nature. 423:2003;742-747.
139. Rodan S.B., et al. Effects of acidic and basic fibroblast growth factors on osteoblastic cells. Connect. Tissue Res. 20:1989;283-288.
140. Saadeh P.B., et al. Mechanisms of fibroblast growth factor-2 modulation of vascular endothelial growth factor expression by osteoblastic cells. Endocrinology. 141:2000;2075-2083.
141. Slootweg M.C., et al. Growth hormone is mitogenic for fetal mouse osteoblasts but not for undifferentiated bone cells. J. Endocrinol. 116:1988;R11-R13.
142. Gould J., et al. Angiogenic activity of anterior pituitary tissue and growth hormone on the chick embryo chorio-allantoic membrane: a novel action of GH. Life Sci. 56:1995;587-594.
143. Ernst M., Froesch E.R. Osteoblastlike cells in a serum-free methylcellulose medium form colonies: effects of insulin and insulinlike growth factor I. Calcif. Tissue Int. 40:1987;27-34.
144. Hansson H.A., et al. Transient expression of insulin-like growth factor I immunoreactivity by vascular cells during angiogenesis. Exp. Mol. Pathol. 50:1989;125-138.
145. Zerega B., et al. Parathyroid hormone [PTH(1-34)] and parathyroid hormone-related protein [PTHrP(1-34)] promote reversion of hypertrophic chondrocytes to a prehypertrophic proliferating phenotype and prevent terminal differentiation of osteoblast-like cells. J. Bone Miner. Res. 14:1999;1281-1289.
146. Carter W.B., et al. Parathyroid-induced angiogenesis is VEGF-dependent. Surgery. 128:2000;458-464.
147. Risau W., et al. Platelet-derived growth factor is angiogenic in vivo. Growth Factors. 7:1992;261-266.
148. Ziche M., et al. Role of prostaglandin E1 and copper in angiogenesis. J. Natl. Cancer Inst. 69:1982;475-482.
149. Yang E.Y., Moses H.L. Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J. Cell Biol. 111:1990;731-741.
150. Breit S., et al. The N-myc oncogene in human neuroblastoma cells: down-regulation of an angiogenesis inhibitor identified as activin A. Cancer Res. 60:2000;4596-4601.
151. Spiro R.C., et al. Inductive activity of recombinant human growth and differentiation factor-5. Biochem. Soc. Trans. 28:2000;362-368.
152. Spiro R.C., et al. Spinal fusion with recombinant human growth and differentiation factor-5 combined with a mineralized collagen matrix. Anat. Rec. 263:2001;388-395.